AdvisorShares Pure Cannabis ETF (YOLO)

Executive Summary

YOLO declined 2.66% to $3.10 since the May 8th report, extending the corrective pattern from the May 7th multi-week high and establishing a new lower low that confirms weakening momentum. The ETF continues to digest the late-April cannabis rescheduling announcement, with market focus shifting from initial policy euphoria to fundamental execution concerns. Despite positive long-term industry projections and the removal of 280E tax burdens, near-term price action suggests investor caution regarding the medical-only scope of immediate rescheduling benefits and uncertainty ahead of June 29th DEA hearings on broader recreational cannabis inclusion.

Key Updates

YOLO declined 2.66% to $3.10 since the May 8th report, breaking below the $3.18-$3.19 support zone established in early May and setting a new multi-session low. The ETF has now retraced 8.1% from the May 7th high of $3.37, confirming that the post-rescheduling rally has stalled. The 1-month performance of +12.91% remains the strongest timeframe, but the 6-month decline of -3.63% and YTD loss of -5.91% indicate persistent structural headwinds despite the historic April 23rd federal rescheduling announcement.

The primary development since the last report is the release of comprehensive cannabis market growth projections showing the global cannabis market expanding from $25.7 billion in 2021 to $148.9 billion by 2031 at a 20.1% CAGR, with North America expected to reach $104.4 billion by 2031. This fundamental backdrop contrasts with YOLO's current price weakness, suggesting a disconnect between long-term industry potential and near-term market sentiment driven by the limited medical-only scope of immediate rescheduling benefits.

Current Trend

YOLO remains in a corrective phase following the late-April rescheduling-driven rally. The ETF established a YTD high near $3.50 in early January before declining to a low of $2.75 in early April, representing a -21.4% drawdown. The April 23rd rescheduling announcement triggered a recovery to $3.37 on May 7th, but the subsequent 8.1% pullback indicates profit-taking and skepticism regarding immediate revenue impact. The current price of $3.10 sits approximately 11.4% below the January YTD high and 12.7% above the April low, positioning the ETF in the middle of its 2026 trading range. The -5.91% YTD performance underperforms broader equity indices and reflects ongoing uncertainty regarding the timeline for full recreational cannabis rescheduling, with critical DEA hearings scheduled for June 29th.

Investment Thesis

The investment thesis for YOLO centers on the historic transition from federal prohibition to regulated cannabis framework, with the April 23rd Schedule III reclassification representing the most significant structural policy shift in decades. The removal of IRS Code 280E restrictions eliminates effective federal tax rates exceeding 70% for cannabis operators, potentially freeing hundreds of millions of dollars annually for reinvestment in operations, employee compensation, and competitive pricing. The long-term growth trajectory remains compelling, with Allied Market Research projecting the global cannabis market to grow nearly six-fold from $25.7 billion in 2021 to $148.9 billion by 2031, driven by continued legalization, expanding medical research, and growing consumer acceptance. However, the medical-only scope of immediate rescheduling creates a bifurcated opportunity set, with pharmaceutical companies developing FDA-approved cannabis medicines positioned to benefit more immediately than state-licensed recreational operators. The June 29th DEA hearing process will determine whether broader rescheduling extends to all state-regulated programs, representing a critical catalyst that could drive fundamental revaluation or extend the current uncertainty period.

Thesis Status

The investment thesis is partially validated but facing near-term execution challenges. The April 23rd rescheduling announcement confirmed the policy direction anticipated by cannabis investors, removing the most significant structural barrier to industry normalization. AdvisorShares' statement characterized the action as establishing conditions for market valuations to be driven by fundamentals rather than federal uncertainty, which supports the long-term thesis. However, the immediate market reaction—with cannabis stocks initially surging then reversing sharply, including a 15% decline in the AdvisorShares Pure US Cannabis ETF on April 24-25—demonstrates investor concern that the medical-only scope limits near-term revenue acceleration. The thesis faces a critical test at the June 29th DEA hearings, where broader rescheduling could extend to recreational programs and validate the full structural improvement narrative. Current price action suggests the market is adopting a "wait-and-see" approach rather than pricing in full thesis realization, creating potential asymmetric opportunity if the June hearings produce favorable outcomes for recreational cannabis inclusion.

Key Drivers

The primary catalyst remains the April 23rd finalization of federal cannabis rescheduling to Schedule III, which AdvisorShares characterized as a critical inflection point moving cannabis from policy gray area into regulated framework. The immediate operational benefit is removal of IRS Code 280E restrictions, with California retailers previously facing effective federal tax rates exceeding 70% now able to deduct business expenses, freeing hundreds of millions of dollars annually across the California market alone. The long-term growth trajectory projects the global cannabis market reaching $148.9 billion by 2031, representing a 20.1% CAGR driven by continued legalization, expanding medical research, and growing consumer acceptance across North America and Europe. However, the medical-only scope of immediate rescheduling created confusion and triggered sharp reversals in cannabis stocks, with YOLO declining 15% on April 24-25 as investors questioned whether limited medical focus would meaningfully drive consumer demand. The critical near-term catalyst is the June 29th expedited DEA hearing on broader rescheduling that could extend Schedule III classification to all state-regulated cannabis programs, potentially resolving current market uncertainty and driving fundamental revaluation.

Technical Analysis

YOLO established a YTD high near $3.50 in early January before entering a corrective phase that reached $2.75 in early April, representing a 21.4% peak-to-trough decline. The April 23rd rescheduling announcement triggered a recovery rally to $3.37 on May 7th, but the subsequent pullback to $3.10 represents an 8.1% decline from that multi-week high and confirms profit-taking pressure. The current price of $3.10 breaks below the $3.18-$3.19 support zone that held on May 6th and 8th, establishing a lower low pattern that signals weakening momentum. Key resistance now sits at $3.18-$3.19 (previous support turned resistance), $3.27 (May 7th level), and $3.37 (May 7th multi-week high). Support levels include $3.00 (psychological round number), $2.85 (mid-April level), and $2.75 (April low). The 1-month gain of +12.91% demonstrates strong recovery momentum from the April low, but the 6-month decline of -3.63% and YTD loss of -5.91% indicate persistent structural headwinds. The recent lower high and lower low pattern suggests consolidation or potential retest of lower support levels unless positive catalysts emerge from the June 29th DEA hearings.

Bull Case

• Global cannabis market projected to grow nearly six-fold from $25.7 billion in 2021 to $148.9 billion by 2031 at 20.1% CAGR, with North America expected to reach $104.4 billion by 2031, providing substantial long-term revenue expansion opportunity for YOLO holdings. Source: PR Newswire
• Removal of IRS Code 280E restrictions frees hundreds of millions of dollars annually for cannabis operators to reinvest in employees, product safety, and competitive pricing, with California retailers previously facing effective federal tax rates exceeding 70% now able to deduct business expenses. Source: PR Newswire
• Schedule III reclassification improves cannabis companies' access to banking systems and institutional capital, removing banking restrictions that previously deterred mainstream investors and financial institutions from supporting cannabis-focused companies. Source: Reuters
• June 29th expedited DEA hearings could extend Schedule III classification to all state-regulated programs, potentially resolving current market uncertainty and driving fundamental revaluation as recreational cannabis operators gain full rescheduling benefits. Source: PR Newswire
• Cannabis industry employs over 400,000 Americans across majority of U.S. states, with AdvisorShares characterizing rescheduling as establishing conditions for market valuations to be driven by fundamentals rather than federal uncertainty. Source: PR Newswire

Bear Case

• Medical-only scope of immediate rescheduling limits near-term revenue acceleration, with cannabis stocks initially surging then reversing sharply as investors questioned whether limited medical focus would meaningfully drive consumer demand, triggering 15% decline in cannabis ETFs on April 24-25. Source: Bloomberg
• YOLO declined 2.66% to $3.10, breaking below $3.18-$3.19 support and establishing lower low pattern that signals weakening momentum and profit-taking following the late-April rescheduling rally, with YTD performance of -5.91% underperforming broader equity indices. Source: Bloomberg
• June 29th DEA hearing outcome remains uncertain, creating extended period of regulatory ambiguity that could limit institutional investor participation and maintain valuation discount until broader recreational cannabis rescheduling is confirmed. Source: PR Newswire
• Individual cannabis company stocks experienced severe volatility post-rescheduling, with Curaleaf Holdings dropping 24% on April 24-25, demonstrating that even positive policy developments can trigger sharp selloffs as investors reassess fundamental valuation and execution risk. Source: Bloomberg
• Pharmaceutical companies with FDA-approved cannabis medicines positioned to benefit more immediately than recreational operators, creating competitive bifurcation where YOLO's state-licensed holdings may lag companies developing Schedule III-compliant pharmaceutical products. Source: Reuters